Trigger point dry needling in the treatment of postherpetic neuralgia: a prospective, randomized controlled study

Phase 1

Recruiting

Conditions: postherpetic neuralgia

Registration Number: ITMCTR2100004300

Lead Sponsor: The First Affiliated Hospital of Jinan University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

(1) The diagnosis of postherpetic neuralgia was based on the Chinese Expert Consensus on the Diagnosis and Treatment of postherpetic neuralgia.
(2) Visual analogue scale(VAS) of pain score above 4.
(3) No contraindications or intolerable adverse reactions to neuropathic pain drugs, such drugs include: pregabalin, amitriptyline, opioids (tramadol, morphine, oxycodone, etc.).
(4) Premenopausal women are willing to confirm birth control measures during the trial.
(5) No other treatment will be given during the trial.
(6) Have normal comprehension and expression ability.

Exclusion Criteria

(1) Patients with other severe chronic pain.
(2) Initiate additional treatment during the trial.
(3) The patient is pregnant or nursing.
(4) Patients with drug or alcohol dependence.
(5) Mental illness that affects patients' judgment or interferes with the conduct of the trial.
(6) Unwilling to accept the review or unable to understand the scale measurement.
(7) Patients with nausea tumor (except patients without recurrence 6 months after radical surgery).
(8) Patients with abnormal coagulation function.
(9) Patients with acute thrombotic events: ischemic stroke, myocardial infarction, pulmonary embolism, deep venous thrombosis, etc.
(10) Unstable angina pectoris.
(11) Renal insufficiency (serum creatinine 1.5 times higher than the normal high value).
(12) The Investigator considers that there are any conditions that could pose a medical risk or affect the outcome of the trial.
(13) Participate in other medical trials during the study period.

Study & Design

Study Type: Interventional study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
VAS score;

Secondary Outcome Measures

Name	Time	Method
Short-form McGill Pain questionnaire;the Patient Health Questionnaire-9 (PHQ-9);Short Form-36 Health Survey (SF-36);Pittsburgh Sleep Quality Index (PSQI);Generalized Anxiety Disorder Scale (GAD-7);